Five promising Swiss startups pitched their ventures from the HEMEX Incubator to renowned Swiss and US investors.
Emovo Care SA is an EPFL spin-off, founded in 2020, developing Emovo Hand – the world’s 1st portable hand orthosis to support care-at-home after a stroke. Based on patent-protected soft robotics technology developed at EPFL, the product provides a natural sensation of moving the hand to hemiparetic stroke patients – to practice functional, comfortable, and intensive exercises at home. Compared to existing solutions, Emovo Hand’s has the additional feature of actively opening the hand – an indispensable function for stroke survivors. Emovo’s connected solution will enable to motivate and measure patients’ progress – to maximize the outcome of care and create value for patients, clinicians, and health insurances.
ASPIVIX SA is a medical technology company specializing in Women’s Health, co-founded by three seasoned experts: a gynecologist, a medtech engineer, and a business leader. CAREVIX™ is a next-generation atraumatic cervical device used in gynecological procedures requiring uterus access. A proprietary vacuum & suction-based technology is used to reduce pain, eliminate bleeding, and tissue tear endured by 80 million women worldwide every year during common procedures such as intra-uterine device insertion and hysteroscopy.
HexagonFab Ltd is a Zurich-based startup, founded in 2018. HexagonFab’s team has developed a new generation of biosensors for rapid and highly sensitive analysis of biomolecules like antibodies, proteins, and small molecules. This award-winning technology, based on graphene nanomaterial, allows pharmaceutical researchers and production staff to monitor biomolecule quality directly at the production line, which offers a $1B market opportunity.
STIMIT AG is a medical device startup founded in 2018 based on a clinical need identified by intensive care and healthcare professionals. A fully functional prototype and physiological proof-of-concept has been developed by the team. STIMIT is using non-invasive technology to stimulate the core breathing muscle (diaphragm) of ventilated intensive care patients. Fifty percent of these patients have significantly weakened breathing muscles after a few days of ventilation, which leads to difficult recovery and oftentimes death.
PreComb Therapeutics AG, founded in 2018, is developing the first point-of-care solution for clinically relevant drug testing, leveraging patient-derived 3D microtissues for drug development and precision medicine. The 3D3 technology has been tailored to meet the critical requirements for the industrialization of patient-specific functional drug testing. 3D microtumors that reflect the original cell composition and microenvironment are produced from small amounts of tissue to generate a high number of drug efficacy data.
Interested in becoming an early-stage investor in one of these promising start-ups or do you want to be kept informed about their progress and future funding rounds / pitch events?
Please contact our start-up scout Franziska Stemmler at +41 61 927 28 02 or franziska.stemmler@hemex.ch
About HEMEX
HEMEX AG is a privately-owned Swiss investment and consulting company headquartered close to the Basel global life sciences hub, with its main focus to bring innovative drugs, medical devices and in vitro diagnostics to the market. HEMEX specializes in supporting early-stage start-ups, offering tailored solutions to accelerate the project into a successful and sustainable business. Additionally, HEMEX helps start-ups in their efforts to find non-dilutive and dilutive funding. More at https://hemex.eu/